March 03, 2023 Spotlight – What's next in Nash The next few months will see some important mid-stage Nash results, from Viking, 89Bio, Northsea and others.
November 03, 2020 AASLD 2020 – Nash updates from Novo and Inventiva in focus At the US liver conference Inventiva will make a case for PPAR agonism, while Novo Nordisk and Gilead’s combo will be scrutinised in Nash.
